Back to Report Store Home

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 – Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

  • Published: Dec-2016
  • Report Code: GBIHC426MR
  • Report Format: pdf

Description

List of Figures

Figure 1: Anti-hypertensive Therapeutics, Global, Hypertension Prevalence Rate (%), 2009–2012 10

Figure 2: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin–Angiotensin–Aldosterone System 13

Figure 3: Anti-hypertensive Therapeutics: Blood Pressure Measurements and Examination of a Patient to Detect Hypertension 16

Figure 4: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension 18

Figure 5: Anti-hypertensive Therapeutics, Combination Therapy Strategies for Blood Pressure Reduction 21

Figure 6: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Hypertension 37

Figure 7: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Pediatrics for the Treatment of Hypertension 38

Figure 8: Anti-hypertensive Therapeutics Market, Global, Pipeline, 2016 41

Figure 9: Anti-hypertensive Therapeutics Market, Global, Pipeline by Molecular Target, 2016 43

Figure 10: Anti-hypertensive Therapeutics, Global, Pipeline by Molecular Target and Stage of Development, 2016 44

Figure 11: Anti-hypertensive Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2016 47

Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006–2015 48

Figure 13: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006–2015 49

Figure 14: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006–2015 50

Figure 15: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006–2015 51

Figure 16: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Type, 2006–2015 52

Figure 17: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006–2015 53

Figure 18: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006–2015 54

Figure 19: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006–2015 55

Figure 20: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type 56

Figure 21: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target 56

Figure 22: Anti-hypertensive Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2015–2022 59

Figure 23: Anti-hypertensive Therapeutics Market, India, Treatment Patterns (million), 2015–2022 60

Figure 24: Anti-hypertensive Therapeutics Market, India, Annual Cost of Therapy ($), 2015–2022 61

Figure 25: Anti-hypertensive Therapeutics Market, India, Market Size ($bn), 2015–2022 62

Figure 26: Anti-hypertensive Therapeutics Market, China, Treatment Patterns (million), 2015–2022 63

Figure 27: Anti-hypertensive Therapeutics Market, China, Annual Cost of Therapy ($), 2015–2022 64

Figure 28: Anti-hypertensive Therapeutics Market, China, Market Size ($bn), 2015–2022 65

Figure 29: Anti-hypertensive Therapeutics Market, Australia, Treatment Patterns (million), 2015–2022 66

Figure 30: Anti-hypertensive Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015–2022 67

Figure 31: Anti-hypertensive Therapeutics Market, Australia, Market Size ($bn), 2015–2022 68

Figure 32: Anti-hypertensive Therapeutics Market, South Korea, Treatment Patterns (million), 2015–2022 69

Figure 33: Anti-hypertensive Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015–2022 70

Figure 34: Anti-hypertensive Therapeutics Market, South Korea, Market Size ($bn), 2015–2022 71

Figure 35: Anti-hypertensive Therapeutics Market, Japan, Treatment Patterns (million), 2015–2022 72

Figure 36: Anti-hypertensive Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015–2022 73

Figure 37: Anti-hypertensive Therapeutics Market, Japan, Market Size ($bn), 2015–2022 74

Figure 38: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Region and Value, 2006–2016 79

Figure 39: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2016 80

Figure 40: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006–2016 81

Figure 41: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006–2016 81

Figure 42: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006–2016 82

Figure 43: Anti-hypertensive Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006–2016 84

Figure 44: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006–2016 85

Figure 45: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006–2016 86

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards